Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): results in the pre‐specified subgroup with heart failure

AIMS: The AMBER trial demonstrated that concomitant use of patiromer enabled the more persistent use of spironolactone by reducing the risk of hyperkalaemia in patients with resistant hypertension and advanced chronic kidney disease. We report herein the pre‐specified subgroup analysis in patients w...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Eur J Heart Fail
Main Authors: Rossignol, Patrick, Williams, Bryan, Mayo, Martha R., Warren, Suzette, Arthur, Susan, Ackourey, Gail, White, William B., Agarwal, Rajiv
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Ltd. 2020
Assuntos:
TREATMENT
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7540031/
https://ncbi.nlm.nih.gov/pubmed/32452085
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.1860
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados